



Clinical Research for Hematopoietic Stem Cell Transplant and Cellular Therapy

Guest Editors:

Dr. Yvonne A. Efebera

Division of Hematology, Blood and Marrow Transplant, OhioHealth, Columbus, OH 43214, USA

Dr. Nidhi Sharma

Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH 43210, USA

Deadline for manuscript submissions:

closed (20 February 2024)

Message from the Guest Editors

Dear Colleagues,

The last ten years have seen significant improvements in the field of hematopoietic stem cell transplantation (HSCT) and cellular therapy for newly diagnosed and relapse/refractory patients with hematologic disorders. Advances in conditioning regimens; the expanding use of alternative donor stem cell sources; and the use of modern T-cell depletion strategies, have led to better survival outcomes and a reduction in incidences of graft versus host disease (GVHD), while improving the graft versus host disease effect in patients undergoing allo-SCT for a wide range of hematologic disorders. Chimeric antigen receptor T-cell (CAR-T) is approved for relapse and refractory lymphoma, multiple myeloma and some leukemias. CAR-T is also being studied in earlier lines of therapy post HSCT, or as an alternative to HSCT.

In this Special Issue, we welcome papers in hematopoietic stem cell transplantation (HSCT) and cellular therapy in newly diagnosed and relapse/refractory hematologic disorders, and the challenges in deciding on the optimal practice.

Dr. Yvonne A. Efebera

Dr. Nidhi Sharma

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)